Europe - Euronext Paris - EPA:VETO - FR0004186856 - Common Stock
The current stock price of VETO.PA is 84.65 EUR. In the past month the price increased by 17.68%. In the past year, price increased by 13.9%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 10.78 | 199.08B | ||
| SNW.DE | SANOFI | 10.83 | 199.86B | ||
| 1SAN.MI | SANOFI | 10.69 | 197.40B | ||
| MRK.DE | MERCK KGAA | 14.95 | 55.43B | ||
| UCB.BR | UCB SA | 39.66 | 49.52B | ||
| UNC.DE | UCB SA | 38.68 | 48.30B | ||
| 1BAYN.MI | BAYER AG-REG | 7.12 | 37.38B | ||
| BAYN.DE | BAYER AG-REG | 7.22 | 37.88B | ||
| IPN.PA | IPSEN | 11.71 | 10.08B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 109.38 | 10.13B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.59 | 10.13B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 21.2 | 8.94B |
Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte and currently employs 2,497 full-time employees. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
VETOQUINOL SA
Sainte-Anne 34 rue du Chene, Bp 189, Lure Cedex
Lure BOURGOGNE-FRANCHE-COMTE FR
Employees: 2519
Phone: 33384625555
Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte and currently employs 2,497 full-time employees. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
The current stock price of VETO.PA is 84.65 EUR. The price decreased by -0.65% in the last trading session.
VETOQUINOL SA (VETO.PA) has a dividend yield of 1.07%. The yearly dividend amount is currently 0.85.
VETO.PA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
VETO.PA stock is listed on the Euronext Paris exchange.
VETOQUINOL SA (VETO.PA) has a market capitalization of 1.01B EUR. This makes VETO.PA a Small Cap stock.
VETOQUINOL SA (VETO.PA) will report earnings on 2026-03-18, after the market close.
ChartMill assigns a technical rating of 8 / 10 to VETO.PA. When comparing the yearly performance of all stocks, VETO.PA turns out to be only a medium performer in the overall market: it outperformed 67.34% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to VETO.PA. VETO.PA has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months VETO.PA reported a non-GAAP Earnings per Share(EPS) of 5.1. The EPS increased by 27.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.26% | ||
| ROA | 8.26% | ||
| ROE | 10.57% | ||
| Debt/Equity | 0.02 |
11 analysts have analysed VETO.PA and the average price target is 92.41 EUR. This implies a price increase of 9.17% is expected in the next year compared to the current price of 84.65.
For the next year, analysts expect an EPS growth of 0.46% and a revenue growth -1.84% for VETO.PA